Literature DB >> 1516254

Predictors of infection in chronic lymphocytic leukaemia (CLL).

H Griffiths1, J Lea, C Bunch, M Lee, H Chapel.   

Abstract

A group of patients with chronic lymphocytic leukaemia (CLL) were studied to determine whether particular clinical and laboratory parameters might help to identify those patients at risk of recurrent infection who would benefit from immunoglobulin replacement therapy. The case notes of 59 patients were reviewed with regard to stage and duration of disease, chemotherapy and frequency of infection over the preceding 2 years. Serum IgG levels and specific antibodies to tetanus, diphtheria and pneumococcal capsular polysaccharide were measured at the end of the 2-year period. A group of 56 healthy age-matched volunteers were used as controls. Eighteen patients had severe or multiple infections during the study period, 11 patients had recurrent infections and the remaining 30 patients had only minimal infections. Overall, serum IgG levels were low in 32 patients but in none of the control group (P = 8.8 x 10(-11). However, less than half of those patients with hypogammaglobulinaemia suffered from severe or multiple infections. Specific antibodies to pneumococcal capsular polysaccharide were low in 23 patients compared with six of the control group (P = 4.9 x 10(-4)). The majority of patients with severe or multiple infections (13/18) had low levels of both total IgG and specific antibodies to pneumococcal capsular polysaccharide. However, in the groups of patients with less frequent infections, a higher proportion had low serum IgG than low pneumococcal antibody levels. Low levels of pneumococcal antibodies were particularly associated with severe or multiple infections (P = less than 0.00001).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1516254      PMCID: PMC1554487          DOI: 10.1111/j.1365-2249.1992.tb06965.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

1.  Clinical staging of chronic lymphocytic leukemia.

Authors:  K R Rai; A Sawitsky; E P Cronkite; A D Chanana; R N Levy; B S Pasternack
Journal:  Blood       Date:  1975-08       Impact factor: 22.113

2.  Hypogammaglobulinaemia in chronic lymphatic leukaemia.

Authors:  G H FAIRLEY; R B SCOTT
Journal:  Br Med J       Date:  1961-10-07

3.  Prophylactic immune globulin in chronic lymphocytic leukemia.

Authors:  E C Besa; D Klumpe
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

4.  Estimation of Corynebacterium diphtheriae antitoxin in human sera: a comparison of an enzyme-linked immunosorbent assay with the toxin neutralisation test.

Authors:  M Melville-Smith; A Balfour
Journal:  J Med Microbiol       Date:  1988-04       Impact factor: 2.472

5.  Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors.

Authors:  H Griffiths; V Brennan; J Lea; C Bunch; M Lee; H Chapel
Journal:  Blood       Date:  1989-02       Impact factor: 22.113

6.  Prognostic factors in chronic lymphocytic leukemia.

Authors:  K R Rai; E Montserrat
Journal:  Semin Hematol       Date:  1987-10       Impact factor: 3.851

7.  Mechanisms of infection in chronic lymphocytic leukemia.

Authors:  H M Chapel; C Bunch
Journal:  Semin Hematol       Date:  1987-10       Impact factor: 3.851

Review 8.  The efficacy of DPT and oral poliomyelitis immunization schedules initiated from birth to 12 weeks of age.

Authors:  N Halsey; A Galazka
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

9.  Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia.

Authors:  J C Weeks; M R Tierney; M C Weinstein
Journal:  N Engl J Med       Date:  1991-07-11       Impact factor: 91.245

  9 in total
  21 in total

1.  Characterization of the impaired antipneumococcal polysacharide antibody production in immunosuppressed pediatric patients following cardiac transplantation.

Authors:  A R Gennery; A J Cant; C I Baldwin; J E Calvert
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

Review 2.  Management of chronic lymphocytic leukaemia.

Authors:  N Kalil; B D Cheson
Journal:  Drugs Aging       Date:  2000-01       Impact factor: 3.923

3.  Antibody deficiency and autoimmunity in 22q11.2 deletion syndrome.

Authors:  A R Gennery; D Barge; J J O'Sullivan; T J Flood; M Abinun; A J Cant
Journal:  Arch Dis Child       Date:  2002-06       Impact factor: 3.791

Review 4.  Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors:  Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal:  J Clin Immunol       Date:  2014-02-21       Impact factor: 8.317

5.  Measurement and interpretation of pneumococcal IgG levels for clinical management.

Authors:  P Balmer; J North; D Baxter; E Stanford; A Melegaro; E B Kaczmarski; E Miller; R Borrow
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

6.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

Review 7.  Immunologic monitoring in chronic lymphocytic leukemia.

Authors:  William G Wierda
Journal:  Curr Oncol Rep       Date:  2003-09       Impact factor: 5.075

8.  Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia.

Authors:  L Varga; E Czink; Z Miszlai; K Pálóczi; A Bányai; G Szegedi; G Füst
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

Review 9.  Adverse effects of intravenous immunoglobulin.

Authors:  S A Misbah; H M Chapel
Journal:  Drug Saf       Date:  1993-10       Impact factor: 5.606

10.  Immunological factors and risk of infection in plateau phase myeloma.

Authors:  R M Hargreaves; J R Lea; H Griffiths; J A Faux; J M Holt; C Reid; C Bunch; M Lee; H M Chapel
Journal:  J Clin Pathol       Date:  1995-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.